Grant: Collaborative Research and Development Grants
University of Alberta
$50,000.00
Novel ultrasonic nanoparticles for cancer sonodynamic therapy
EF 2012-13
Résumé
Controlled drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. For most therapeutic drugs, only a small portion of the medication reaches the organ to be affected. Controlled drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues. Currently, more than 40% of drugs are poorly water-soluble or water-insoluble. Because poor-soluble drugs partially dissolved in aqueous media, desirable drug effect is difficult to achieve. Without proper coating, drugs may be pre-maturely released due to complicated body conditions before reaching targeted organs. In addition, kidneys promote rapidly clearance of drugs from the bloodstream, requiring higher doses or continuous infusion to achieve therapeutic effect, while also undesirably increases drug side effects. One of the most promising areas in controlled drug delivery is formulation using state-of-the-art nanotechnology. In collaboration with IntelligentNano Inc. based in Edmonton, Alberta, we propose a novel bi-layer nanoformulation design to achieve ultrasound controlled drug delivery. The proposed research idea is as follows. We encapsulate drugs inside bio-compatible and hydrophilic nano-scale bubbles (the first layer coating). When these nano-bubbles circulated inside the human body, the encapsulated drugs cannot be released due to the special second-layer coating of these nano-bubbles. However, these bubbles will burst only when external ultrasound of specific frequency strikes them because the second-layer coating is ultrasound-sensitive. The project meets the objectives of the NSERC CRD program by (i) giving Canadian company to access the unique knowledge, expertise, and educational resources available at Canadian university; (ii) training students in essential technical cross-disciplinary skills required by emerging biotechnology industry. The mutually beneficial collaborations are expected to result in economic benefits in drug delivery area to Canada.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
376054-2008
Name nom
Chen, Jie
Department département
Electrical and Computer Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2008
Award amount
50000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
3
Application title
Novel ultrasonic nanoparticles for cancer sonodynamic therapy
Keyword
NSERC
Application summary
Controlled drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. For most therapeutic drugs, only a small portion of the medication reaches the organ to be affected. Controlled drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues. Currently, more than 40% of drugs are poorly water-soluble or water-insoluble. Because poor-soluble drugs partially dissolved in aqueous media, desirable drug effect is difficult to achieve. Without proper coating, drugs may be pre-maturely released due to complicated body conditions before reaching targeted organs. In addition, kidneys promote rapidly clearance of drugs from the bloodstream, requiring higher doses or continuous infusion to achieve therapeutic effect, while also undesirably increases drug side effects. One of the most promising areas in controlled drug delivery is formulation using state-of-the-art nanotechnology. In collaboration with IntelligentNano Inc. based in Edmonton, Alberta, we propose a novel bi-layer nanoformulation design to achieve ultrasound controlled drug delivery. The proposed research idea is as follows. We encapsulate drugs inside bio-compatible and hydrophilic nano-scale bubbles (the first layer coating). When these nano-bubbles circulated inside the human body, the encapsulated drugs cannot be released due to the special second-layer coating of these nano-bubbles. However, these bubbles will burst only when external ultrasound of specific frequency strikes them because the second-layer coating is ultrasound-sensitive. The project meets the objectives of the NSERC CRD program by (i) giving Canadian company to access the unique knowledge, expertise, and educational resources available at Canadian university; (ii) training students in essential technical cross-disciplinary skills required by emerging biotechnology industry. The mutually beneficial collaborations are expected to result in economic benefits in drug delivery area to Canada.